沙库巴曲缬沙坦在心力衰竭中的肾脏保护作用：来自真实临床环境的见解 - Suppr

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

作者信息

Mulè Giuseppe, Sorce Alessandra, Nardi Emilio, Geraci Giulio, Cottone Santina

机构信息

Unit of Nephrology and Hypertension, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, European Society of Hypertension Excellence Centre, University of Palermo, Via Monte San Calogero, 29, 90146, Palermo, Italy.

Dipartimento di Scienze della Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica d'Eccellenza "G. D'Alessandro" (PROMISE), Unit of Internal Medicine, University of Palermo, Palermo, Italy.

出版信息

Intern Emerg Med. 2019 Nov;14(8):1205-1208. doi: 10.1007/s11739-019-02149-6. Epub 2019 Jul 15.

DOI:10.1007/s11739-019-02149-6

PMID:31309521

Abstract

摘要

相似文献

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Intern Emerg Med. 2019 Nov;14(8):1205-1208. doi: 10.1007/s11739-019-02149-6. Epub 2019 Jul 15.

Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.

Cardiovasc Drugs Ther. 2019 Jun;33(3):307-314. doi: 10.1007/s10557-019-06858-0.

Insights into implementation of sacubitril/valsartan into clinical practice.

ESC Heart Fail. 2018 Jun;5(3):275-283. doi: 10.1002/ehf2.12258. Epub 2018 Feb 21.

Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.

Acta Cardiol. 2019 Apr;74(2):115-122. doi: 10.1080/00015385.2018.1473825. Epub 2018 Jun 17.

Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.

Heart Lung Circ. 2020 Sep;29(9):1310-1317. doi: 10.1016/j.hlc.2019.03.007. Epub 2019 Apr 2.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.

Ir J Med Sci. 2019 Nov;188(4):1169-1174. doi: 10.1007/s11845-019-01990-0.

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.

Open Heart. 2020 Oct;7(2). doi: 10.1136/openhrt-2020-001305.

Circ Heart Fail. 2017 Aug;10(8). doi: 10.1161/CIRCHEARTFAILURE.116.003430.

Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.

Pharmacotherapy. 2019 Nov;39(11):1053-1059. doi: 10.1002/phar.2328. Epub 2019 Oct 10.

本文引用的文献

Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.

Intern Emerg Med. 2019 Nov;14(8):1287-1297. doi: 10.1007/s11739-019-02111-6. Epub 2019 May 30.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.

Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.

Exploiting the Natriuretic Peptide Pathway to Preserve Glomerular Filtration in Heart Failure.

JACC Heart Fail. 2018 Jun;6(6):499-502. doi: 10.1016/j.jchf.2018.02.017. Epub 2018 Apr 11.

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.

Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk.

High Blood Press Cardiovasc Prev. 2017 Jun;24(2):115-126. doi: 10.1007/s40292-017-0196-1. Epub 2017 Apr 4.

Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.

Int J Cardiol. 2017 Jan 1;226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.

Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.

High Blood Press Cardiovasc Prev. 2015 Sep;22(3):241-6. doi: 10.1007/s40292-015-0112-5. Epub 2015 Jun 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

作者信息

Mulè Giuseppe, Sorce Alessandra, Nardi Emilio, Geraci Giulio, Cottone Santina

机构信息

出版信息

Intern Emerg Med. 2019 Nov;14(8):1205-1208. doi: 10.1007/s11739-019-02149-6. Epub 2019 Jul 15.

DOI:10.1007/s11739-019-02149-6

PMID:31309521

Abstract

摘要

相似文献

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Intern Emerg Med. 2019 Nov;14(8):1205-1208. doi: 10.1007/s11739-019-02149-6. Epub 2019 Jul 15.

Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.

Cardiovasc Drugs Ther. 2019 Jun;33(3):307-314. doi: 10.1007/s10557-019-06858-0.

Insights into implementation of sacubitril/valsartan into clinical practice.

ESC Heart Fail. 2018 Jun;5(3):275-283. doi: 10.1002/ehf2.12258. Epub 2018 Feb 21.

Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.

Acta Cardiol. 2019 Apr;74(2):115-122. doi: 10.1080/00015385.2018.1473825. Epub 2018 Jun 17.

Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.

Heart Lung Circ. 2020 Sep;29(9):1310-1317. doi: 10.1016/j.hlc.2019.03.007. Epub 2019 Apr 2.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.

Ir J Med Sci. 2019 Nov;188(4):1169-1174. doi: 10.1007/s11845-019-01990-0.

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.

Open Heart. 2020 Oct;7(2). doi: 10.1136/openhrt-2020-001305.

Circ Heart Fail. 2017 Aug;10(8). doi: 10.1161/CIRCHEARTFAILURE.116.003430.

Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.

Pharmacotherapy. 2019 Nov;39(11):1053-1059. doi: 10.1002/phar.2328. Epub 2019 Oct 10.

本文引用的文献

Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.

Intern Emerg Med. 2019 Nov;14(8):1287-1297. doi: 10.1007/s11739-019-02111-6. Epub 2019 May 30.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.

Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.

Exploiting the Natriuretic Peptide Pathway to Preserve Glomerular Filtration in Heart Failure.

JACC Heart Fail. 2018 Jun;6(6):499-502. doi: 10.1016/j.jchf.2018.02.017. Epub 2018 Apr 11.

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.

Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk.

High Blood Press Cardiovasc Prev. 2017 Jun;24(2):115-126. doi: 10.1007/s40292-017-0196-1. Epub 2017 Apr 4.

Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.

Int J Cardiol. 2017 Jan 1;226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.

Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.

Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.

High Blood Press Cardiovasc Prev. 2015 Sep;22(3):241-6. doi: 10.1007/s40292-015-0112-5. Epub 2015 Jun 23.

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

作者信息

机构信息

出版信息

相似文献

本文引用的文献